A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration

NCT02194166 | Completed Phase 3

• 1 other identifier: ML28839
• Study Type: interventional
• Target: 90
• Locations: 2 countries
• Sites: 7

Brief Summary

This multicenter study in participants with HER2-positive eBC will investigate participants' pain and discomfort of SC trastuzumab (Herceptin) administered either via a single-use injection device (SID) or via vial for manual administration using a hand-held syringe (SC vial). In total, participants will obtain at least 18 cycles/1 year of trastuzumab (4 cycles of intravenous \[IV\] and 14 cycles of SC trastuzumab).

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (2)

• Participant Pain as Measured on a 10 Centimeter (cm) Visual Analogue Scale

  Week 13 up to Week 52

• Participant Discomfort as Measured on a 10 cm Visual Analogue Scale

  Week 13 up to Week 52

Secondary Outcomes (12)

• Healthcare Professional Satisfaction With SC Formulation as Assessed by Health Care Professional Questionnaire (HCPQ)

  Week 22

• Patient Satisfaction With SC Formulation as Assessed by Patients Satisfaction Questionnaire (PSQ)

  Week 52

• Healthcare Professional Perceived Time Savings With SC Trastuzumab as Assessed by HCPQ

  Week 22

• Percentage of Participants With Adverse Events

  Baseline up to approximately 3 years

• Overall Survival

  From first study treatment to death from any cause, assessed up to approximately 4.5 years

Study Arms (3)

Pre-Randomization (Trastuzumab IV)

EXPERIMENTAL

Trastuzumab IV will be given during the first 4 cycles for all participants before randomization for SC administration. A dose of 6 milligrams per kilogram (mg/kg) will be given every 3 weeks. All the participants will require a loading dose on Day 1 of Cycle 1, so they will receive 8 mg/kg followed by 6 mg/kg, 3 weeks later and then 3-weekly. Concurrent administration during the first 4 cycles of trastuzumab IV with paclitaxel/docetaxel will have to be performed in accordance with local hospital practice.

Drug: Trastuzumab; Drug: Paclitaxel; Drug: Docetaxel

Group A: Trastuzumab SC (First Vial Formulation, then SID)

EXPERIMENTAL

Participants will receive 7 cycles of SC trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation) followed by 7 cycles of SC trastuzumab 600 mg SID administration after cross-over.

Drug: Trastuzumab

Group B: Trastuzumab SC (First SID, then Vial Formulation)

EXPERIMENTAL

Participants will start with 7 cycles of SC trastuzumab 600 mg administration via SID and after cross-over will receive 7 injections of trastuzumab 600 mg with assisted administration using a conventional syringe and needle (SC vial formulation).

Drug: Trastuzumab

Interventions

Trastuzumab DRUG

Trastuzumab IV or SC will be administered as described.

Also known as: Herceptin

Group A: Trastuzumab SC (First Vial Formulation, then SID); Group B: Trastuzumab SC (First SID, then Vial Formulation); Pre-Randomization (Trastuzumab IV)

Paclitaxel DRUG

Paclitaxel will be administered in accordance with local hospital practice.

Pre-Randomization (Trastuzumab IV)

Docetaxel DRUG

Docetaxel will be administered in accordance with local hospital practice.

Pre-Randomization (Trastuzumab IV)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Hormonal therapy allowed as per institutional guidelines
• Left ventricular ejection fraction (LVEF) of greater than or equal to (\>/=) 55 percent (%) measured by echocardiography (ECHO) prior to first dose of trastuzumab
• HER2-positive disease immunohistochemistry (IHC) 3+ or in-situ hybridization (ISH) positive as determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay
• Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast
• No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, or during concurrent chemotherapy (neo-adjuvant or adjuvant)
• Participants who have completed all (neo)adjuvant treatment or participants after adjuvant chemotherapy with doxorubicin and cyclophosphamide (AC) to whom the 4 subsequent cycles of trastuzumab in combination with paclitaxel or docetaxel are indicated per local practice
• Not more than 3 months should have elapsed since the last dose of adjuvant chemotherapy in case of subsequent treatment scheme

You may not qualify if:

• Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent
• History of other malignancy that can affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and participants with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible. Participants with previous ductal carcinoma in situ (DCIS) of the breast are also eligible for the study
• Participants with severe dyspnea at rest or requiring supplementary oxygen therapy
• Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
• Prior maximum cumulative dose of doxorubicin \>360 mg/m2 or maximum cumulative dose of epirubicin \>720 mg/m2 or equivalent
• Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension
• Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)
• Pregnant or lactating women
• Concurrent enrollment in another clinical trial using an investigational anticancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment
• Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin®, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g., difficult to control asthma
• Inadequate bone marrow, hepatic, or renal function
• Major surgical procedure or significant traumatic injury within 14 days prior to the first dose of study treatment or anticipated need for major surgery during the course of study treatment

Sponsors & Collaborators

• Hoffmann-La Roche: lead

Study Sites (7)

State Inst N.N. Alexandrov Republican Scientific & Practical Centre of Oncology & Medical Radiology

A/g Lesnoy, Minsk Region, 223040, Belarus

Location

Healthcare Institution "Brest Regional Oncologic Dispensary"

Brest, 224027, Belarus

Location

Minsk City Clinical Oncologic Dispensary

Minsk, BU-220013, Belarus

Location

Vitebsk Regional Clinical Oncology Dispensary

Vitebsk, BU-210603, Belarus

Location

Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department

Almaty, 050022, Kazakhstan

Location

Almaty Cancer Hospital; Chemotherapy department

Almaty, 050054, Kazakhstan

Location

Oncology centre of Astana; Chemotherapy department

Astana, 010000, Kazakhstan

Location

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Trastuzumab; Paclitaxel; Docetaxel

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Study Officials

• Clinical Trials

  Hoffmann-La Roche

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 8, 2014
• First Posted: July 18, 2014
• Study Start: July 18, 2014
• Primary Completion: July 12, 2018
• Study Completion: July 12, 2018
• Last Updated: June 10, 2019

Record last verified: 2019-06

Locations

KA (3); BE (4)